NRX Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
NRX Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2024.
  • NRX Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -133 %, a 96.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -133 +4.21K +96.9% Sep 30, 2024
Q2 2024 -157 -494 -147% Jun 30, 2024
Q1 2024 -223 -336 -297% Mar 31, 2024
Q4 2023 -395 -451 -806% Dec 31, 2023
Q3 2023 -4.34K -4.38K -10636% Sep 30, 2023
Q2 2023 337 +259 +330% Jun 30, 2023
Q1 2023 113 -448 -79.9% Mar 31, 2023
Q4 2022 55.9 +2.79K Dec 31, 2022
Q3 2022 41.2 +255 Sep 30, 2022
Q2 2022 78.4 +219 Jun 30, 2022
Q1 2022 561 +684 Mar 31, 2022
Q4 2021 -2.74K -2.64K -2833% Dec 31, 2021
Q3 2021 -214 -160 -299% Sep 30, 2021
Q2 2021 -141 -55.4 -64.8% Jun 30, 2021
Q1 2021 -124 +877 +87.6% Mar 31, 2021
Q4 2020 -93.3 -183 -204% Dec 31, 2020
Q3 2020 -53.5 -92.4 -238% Sep 30, 2020
Q2 2020 -85.5 Jun 30, 2020
Q1 2020 -1K Mar 31, 2020
Q4 2019 89.6 Dec 31, 2019
Q3 2019 38.9 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.